170 results
Page 2 of 9
6-K
EX-99.1
1xc sgk74967c2mz2
31 May 23
Report of Foreign Private Issuer
8:09am
6-K
EX-99.1
no8miu 4i
8 May 23
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to
8:02am
6-K
EX-99.1
h9ptk5sgy8d5dboi41o
19 Apr 23
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
8:03am
6-K
EX-99.1
v4qv1w87x2yw0qn5ihf
17 Apr 23
Enlivex Appoints Andrew Singer to its Board of Directors
8:03am
6-K
EX-99.1
cq3gy9d9p2pb3tk5
4 Apr 23
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
8:05am
6-K
EX-99.1
ajo0xhoasm4
3 Apr 23
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
8:05am
6-K
EX-99.1
bex gwnmppo5vw
31 Mar 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-10.1
l593bpzmap 54
30 Dec 22
Report of Foreign Private Issuer
4:02pm
424B5
kw4xqy67i0r8
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.1
64c3jgw1y187ec do
5 Dec 22
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
8:05am
6-K
EX-99.2
h2b68iuy3vhvhi
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
qualgk3tvc302jsh231q
28 Nov 22
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
8:01am
6-K
EX-99.1
6l8o 9m4rgy
15 Nov 22
Report of Foreign Private Issuer
8:01am
6-K
EX-99.1
hcmzp w4g8
12 Sep 22
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
s4zk99l11xmvov o64hb
6 Sep 22
Report of Foreign Private Issuer
8:06am
6-K
EX-99.1
xpqiubcq7zj
29 Aug 22
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
8:01am
6-K
EX-99.1
go53v8uau
24 Aug 22
Report of Foreign Private Issuer
8:05am
6-K
EX-99.2
fpy51dd hjivxqky4
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.3
4n4qpm4 4wnv1
22 Aug 22
Condensed Consolidated Financial Statements
8:08am